Biogen Idec Launches MS Drug Tysabri, Avonex Pen In Japan
This article was originally published in PharmAsia News
Executive Summary
Biogen Idec Japan has launched the humanized monoclonal antibody Tysabri 300 mg (natalizumab) infusion for multiple sclerosis treatment and the interferon beta agent Avonex (interferon beta-1a) Pen on June 4, the company announced on the same day.